-

09:11:41 PM

ETON Stock News

ETON - Eton Pharmaceuticals Inc

08/16/21 4:02 PM

Nasdaq : ETON

earnings

Eton Pharmaceuticals Reports Second Quarter Financial Results

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021. “During the second

RHEA-AI

neutral

08/03/21 4:05 PM

Nasdaq : ETON

conferencesearnings

Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on

RHEA-AI

neutral

06/15/21 4:05 PM

Nasdaq : ETON

acquisition

Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector

Expands Eton’s Adrenal Insufficiency Orphan Drug Portfolio ZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone Proprietary ZENEO® Needleless Device is Covered by 24 U.S. Patents Extending as Far as 2037 DEER PARK,

RHEA-AI

neutral

06/15/21 10:37 AM

Nasdaq : ETON

fda approval

Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)

Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres ® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting

RHEA-AI

very positive

05/28/21 8:05 AM

Nasdaq : ETON

Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection

Eton Pharmaceuticals, Inc (Nasdaq: ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for dehydrated

RHEA-AI

neutral

05/13/21 4:05 PM

Nasdaq : ETON

earnings

Eton Pharmaceuticals Reports Record Revenue and Earnings

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical

RHEA-AI

neutral

05/04/21 4:05 PM

Nasdaq : ETON

conferencesearnings

Eton Pharmaceuticals to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2021 financial and operating results on

RHEA-AI

neutral

03/17/21 4:05 PM

Nasdaq : ETON

management

Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17,

RHEA-AI

neutral

03/16/21 4:02 PM

Nasdaq : ETON

earnings

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020

RHEA-AI

neutral

03/04/21 4:05 PM

Nasdaq : ETON

conferencesearnings

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16, 2021

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report fourth quarter and full year 2020

RHEA-AI

neutral